Acticor Biotech, a France clinical-stage biotechnology company, is a spin-off company from INSERM (French National Institute of Health and Medical Research) founded in November 2013, dedicated to developing an innovative first-in-class treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke. Acticor Biotech is built upon the expertise and the results of researches conducted by its founders: Dr. Martine Jandrot- Perrus at INSERM Paris and Professor Philippe Billiald at Paris-Sud University. For more information about Acticor Biotech, please visit www.acticor-biotech.com.
ACT017 is a high affinity humanized antibody fragment (Fab) directed against the platelet glycoprotein VI (GPVI). It works quickly via IV administration, and the possibility of drug accumulation is relatively small for a short half-life. ACT017 plays an anti-platelet effect through blocking off platelet recruitment, adhesion and aggregation by inhibiting collagen-binding on GPVI and blocking subsequent GPVI-mediated signaling. Its mechanism is novel, and it is probably safer than existing antiplatelet agents because of blocking pathological platelet aggregation without inducing detrimental effects on physiologic hemostasis.
In February 2022, the Group’s partner Acticor Biotech announced that the ACTIMIS phase 1b/2a study in patients with acute ischemic stroke has met its primary endpoint, and the incidences of symptomatic intracerebral hemorrhage (ICH), asymptomatic ICH and deaths were lower versus placebo.
Ischemic stroke is characterized by high morbidity, high disability and high mortality, accounting for approximately 60%-80% of all strokes. It is estimated that nearly 2 million new strokes occur every year in China, resulting in approximately 1.2-1.6 million patients suffering from ischemic stroke attack for the first time annually.
